-
April 16, 2024
R & D
PDF282 KB
Nippon Shinyaku Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW
-
April 04, 2024
R & D
PDF266 KB
Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System
-
March 26, 2024
Pharmaceuticals
PDF297 KB
Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan
-
March 26, 2024
Pharmaceuticals
PDF303 KB
UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan
-
March 25, 2024
R & D
PDF279 KB
Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan
-
March 06, 2024
R & D
PDF262 KB
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
-
February 27, 2024
R & D
PDF252 KB
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data Scheduled for Presentation at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
-
February 09, 2024
R & D
PDF239 KB
Nippon Shinyaku and Vicore Pharma enter into an Exclusive License Agreement to Develop and Commercialize C21 for the treatment of Idiopathic Pulmonary Fibrosis in Japan
-
February 09, 2024
Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2023
-
January 22, 2024
R & D
PDF263 KB
The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
